Dong, Yu

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Chu, T., Zhong, R., Zhong, H., Zhang, B., Zhang, W., Shi, C., Qian, J., Zhang, Y., Chang, Q., Zhang, X., et al. (2021) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 227

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

Tang, K., Zhao, M., Wu, Y.-H., Wu, Q., Wang, S., Dong, Y., Yu, B., Song, Y., & Liu, H.-M. (2022) · European Journal of Medicinal Chemistry

Protein Tyrosine PhosphatasesComputational Drug Discovery Methods

Cited by 20